Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury

Cell Death and Disease

Volumn 6, Issue 5, 2015, Pages

  Deutsch, M ^a   Graffeo, C S ^a   Rokosh, R ^a   Pansari, M ^a   Ochi, A ^a   Levie, E M ^a   Van Heerden, E ^a   Tippens, D M ^a   Greco, S ^a   Barilla, R ^a   Tomkotter L ^a   Zambirinis, C P ^a   Avanzi, N ^a   Gulati, R ^a   Pachter, H L ^a   Torres Hernandez, A ^a   Eisenthal, A ^a   Daley, D ^a   Miller, G ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; INFLAMMASOME; LIVER PROTEIN; NECROSTATIN 1; PARACETAMOL; PROTEIN INHIBITOR; RECEPTOR INTERACTING PROTEIN 1; RECEPTOR INTERACTING PROTEIN 3; UNCLASSIFIED DRUG; CARRIER PROTEIN; CASPASE 8; CCL2 PROTEIN, MOUSE; CRYOPYRIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NLRP3 PROTEIN, MOUSE; RALBP1 PROTEIN, MOUSE; REACTIVE OXYGEN METABOLITE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; ENZYME INHIBITION; INFLAMMATION; LIVER CELL; LIVER INJURY; MALE; MOUSE; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INJURIES; KNOCKOUT MOUSE; LIVER; METABOLISM; NECROSIS; PATHOLOGY;

ACETAMINOPHEN; ANIMALS; APOPTOSIS; CARRIER PROTEINS; CASPASE 8; CHEMOKINE CCL2; CONCANAVALIN A; DISEASE MODELS, ANIMAL; GTPASE-ACTIVATING PROTEINS; HEPATITIS, AUTOIMMUNE; HEPATOCYTES; INTERLEUKIN-6; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NECROSIS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; REACTIVE OXYGEN SPECIES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84970916712     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.126     Document Type: Article

References (50)

1. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009; 43: 342-349.
2. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS et al. Acetaminopheninduced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-1372.
3. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 2004; 40: 6-9.
4. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008; 14: 3374-3387.
5. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.
6. Murphy N. An update in acute liver failure: when to transplant and the role of liver support devices. Clin Med 2006; 6: 40-46.
7. Fang X, Wang R, Ma J, Ding Y, Shang W, Sun Z. Ameliorated ConA-induced hepatitis in the absence of PKC-theta. PLoS One 2012; 7: e31174.
8. Higashimoto M, Sakai Y, Takamura M, Usui S, Nasti A, Yoshida K et al. Adipose tissue derived stromal stem cell therapy in murine ConA-derived hepatitis is dependent on myeloidlineage and CD4+ T-cell suppression. Eur J Immunol 2013; 43: 2956-2968.
9. Nakaya M, Hashimoto M, Nakagawa R, Wakabayashi Y, Ishizaki T, Takada I et al. SOCS3 in T and NKT cells negatively regulates cytokine production and ameliorates ConA-induced hepatitis. J Immunol 2009; 183: 7047-7053.
10. Connolly MK, Ayo D, Malhotra A, Hackman M, Bedrosian AS, Ibrahim J et al. Dendritic cell depletion exacerbates acetaminophen hepatotoxicity. Hepatology 2011; 54: 959-968.
11. Han D, Shinohara M, Ybanez MD, Saberi B, Kaplowitz N. Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol 2010: 267-310.
12. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003; 31: 1499-1506.
13. Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 2006; 89: 31-41.
14. Gardner CR, Laskin JD, Dambach DM, Sacco M, Durham SK, Bruno MK et al. Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis factor-alpha and interleukin-10. Toxicol Appl Pharmacol 2002; 184: 27-36.
15. Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J 2002; 16: 1227-1236.
16. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004; 127: 1760-1774.
17. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009; 119: 305-314.
18. Williams CD, Antoine DJ, Shaw PJ, Benson C, Farhood A, Williams DP et al. Role of the Nalp3 inflammasome in acetaminophen-induced sterile inflammation and liver injury. Toxicol Appl Pharmacol 2011; 252: 289-297.
19. Kon K, Ikejima K, Okumura K, Aoyama T, Arai K, Takei Y et al. Role of apoptosis in acetaminophen hepatotoxicity. J Gastroenterol Hepatol 2007; 22(Suppl 1): S49-S52.
20. Zhang YF, He W, Zhang C, Liu XJ, Lu Y, Wang H et al. Role of receptor interacting protein (RIP)1 on apoptosis-inducing factor-mediated necroptosis during acetaminophen-evoked acute liver failure in mice. Toxicol Lett 2014; 225: 445-453.
21. Takemoto K, Hatano E, Iwaisako K, Takeiri M, Noma N, Ohmae S et al. Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminopheninduced acute liver failure. FEBS Open Bio 2014; 4: 777-787.
22. Li JX, Feng JM, Wang Y, Li XH, Chen XX, Su Y et al. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis 2014; 5: e1278.
23. Ni HM, Chen X, Ding WX, Schuchmann M, Yin XM. Differential roles of JNK in ConA/GalN and ConA-induced liver injury in mice. Am J Pathol 2008; 173: 962-972.
24. Zhou Y, Dai W, Lin C, Wang F, He L, Shen M et al. Protective effects of necrostatin-1 against concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm 2013; 2013: 706156.
25. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, Van Herreweghe F et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ 2012; 19: 2003-2014.
26. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
27. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
28. Han W, Xie J, Li L, Liu Z, Hu X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 2009; 14: 674-686.
29. Ramachandran A, McGill MR, Xie Y, Ni HM, Ding WX, Jaeschke H. Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice. Hepatology 2013; 58: 2099-2108.
30. Beland K, Lapierre P, Alvarez F. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J Gastroenterol 2009; 15: 1025-1034.
31. Bittencourt PL, Goldberg AC, Cancado EL, Porta G, Carrilho FJ, Farias AQ et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999; 94: 1906-1913.
32. Guindi M. Histology of autoimmune hepatitis and its variants. Clin Liver Dis 2010; 14: 577-590.
33. Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009; 29: 286-296.
34. Chen J, Duan L, Xiong A, Zhang H, Zheng F, Tan Z et al. Blockade of IL-33 ameliorates Con A-induced hepatic injury by reducing NKT cell activation and IFN-gamma production in mice. J Mol Med (Berl) 2012; 90: 1505-1515.
35. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 2007; 117: 2302-2312.
36. Jiang W, Sun R, Zhou R, Wei H, Tian Z. TLR-9 activation aggravates concanavalin A-induced hepatitis via promoting accumulation and activation of liver CD4+ NKT cells. J Immunol 2009; 182: 3768-3774.
37. Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ 2013; 20: 366.
38. Christofferson DE, Li Y, Hitomi J, Zhou W, Upperman C, Zhu H et al. A novel role for RIP1 kinase in mediating TNFalpha production. Cell Death Dis 2012; 3: e320.
39. Jagtap PG, Degterev A, Choi S, Keys H, Yuan J, Cuny GD. Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem 2007; 50: 1886-1895.
40. Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014; 56: 481-495.
41. Moriwaki K, Chan FK. Necrosis-dependent and independent signaling of the RIP kinases in inflammation. Cytokine Growth Factor Rev 2014; 25: 167-174.
42. Weinlich R, Oberst A, Dillon CP, Janke LJ, Milasta S, Lukens JR et al. Protective roles for caspase-8 and cFLIP in adult homeostasis. Cell Rep 2013; 5: 340-348.
43. Jaeschke H. Innate immunity and acetaminophen-induced liver injury: why so many controversies? Hepatology 2008; 48: 699-701.
44. Ishida Y, Kondo T, Kimura A, Tsuneyama K, Takayasu T, Mukaida N. Opposite roles of neutrophils and macrophages in the pathogenesis of acetaminophen-induced acute liver injury. Eur J Immunol 2006; 36: 1028-1038.
45. Ju C, Reilly TP, Bourdi M, Radonovich MF, Brady JN, George JW et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem Res Toxicol 2002; 15: 1504-1513.
46. Lawson JA, Farhood A, Hopper RD, Bajt ML, Jaeschke H. The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. Toxicol Sci 2000; 54: 509-516.
47. Liu ZX, Han D, Gunawan B, Kaplowitz N. Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology 2006; 43: 1220-1230.
48. Masson MJ, Carpenter LD, Graf ML, Pohl LR. Pathogenic role of natural killer T and natural killer cells in acetaminophen-induced liver injury in mice is dependent on the presence of dimethyl sulfoxide. Hepatology 2008; 48: 889-897.
49. Michael SL, Pumford NR, Mayeux PR, Niesman MR, Hinson JA. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 1999; 30: 186-195.
50. Connolly MK, Bedrosian AS, Mallen-St Clair J, Mitchell AP, Ibrahim J, Stroud A et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009; 119: 3213-3225.